Levomepromazine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Levomepromazine

Examples of brand names: Neurocil [DE]

ATC code: N05AA02

Main use (for orientation): Psychoses; severe agitation

Documented research summary

No direct study of the pair. Mechanistic possibilities remain unquantified; no demonstrated combination toxicity.

Uncertainties and limitations

Cell/animal models and uncontrolled observations cannot be directly applied to clinical dosing decisions.

Rare cannabinoids within the scope of 28 remain poorly documented where pair-specific findings are absent.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Levomepromazine: CYP3A4/1A2 laboratory context, CYP2D6 inhibition; sedation/hypotension.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral Levomepromazine Maleate [UK]; schizophrenia and palliative relief of pain/distress; N05AA02 D2/alpha/muscarinic/H1 effects; sedation, additive CNS/respiratory depression, hypotension and QT risk. Not a prodrug.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0136]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Levomepromazine Maleate50mg [C_LABEL_D0136]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[C_LABEL_D0136] Levomepromazine Maleate50mg

Original source / bibliographic reference

Authors: Pharmaceutical company not separately entered in the source field; product / official product information identified by title and URL

Year: 2023

Source type: Product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility